ad
Errata to 2009 Red Book®

Updated 4/4/11

Print-Friendly PDF Version

  1. Page IV The following individuals should be added to the list of Collaborators:
    • Mark Abramowicz, MD, The Medical Letter Inc, New Rochelle, NY
    • William L. Atkinson, MD, MPH, Centers for Disease Control and Prevention, Atlanta, GA
    • John A. Vanchiere, MD, PhD, Louisiana State University Health Sciences Center, Shreveport, LA
  2. Page 355: In Table 3.22, last column, under "Unknown or Not Tested," the second bullet should be changed from If inadequate, no treatment to If adequate, no treatment. Posted 6/29/09

  3. Page 494: Under Epidemiology, the 5th sentence should be changed from Human-to-human spread has not been documented. to Human-to-human spread has been documented vertically from mother to neonate, horizontally from colonized humans, and by contaminated blood products. Posted 8/17/09

  4. Page 507: In Table 3.44, in the adolescents and adults row, last column, the text should be changed from TMP, 200 mg/day to TMP, 320 mg/day. Posted 6/18/10

  5. Page 539: Treatment section, in the 2nd paragraph under the Chemoprophylaxis heading, in the 2nd sentence beginning “Prophylaxis for PCP should be discontinued…”, a portion of the text should be changed from and 1 performed at 24 months of age or older to and 1 performed at 4 months of age or older. Posted 1/13/10

  6. Page 566: In Table 3.61, in the May row, under "29 Weeks, 0 Days Through 31 Weeks, 6 Days of Gestation and <6 Months of Age at Start of Season," the maximum number of doses should be changed from 0d to 5. Posted 7/17/09

  7. Page 645: In Table 3.75, under “Clinical Status,” the text for (a)(iv) should be changed from maternal evidence of reinfection or relapse (less than fourfold decrease in titers) to maternal evidence of reinfection or relapse (fourfold or greater increase in titers). Posted 8/17/09

  8. Pages 745-746: In Table 4.1, the following changes should be made:
    • In the first column, the footnote e notation next to Carbapenems and Metronidazole should be removed.
    • In the first column, the footnote e notation next to Ampicillin should be changed to a footnote d notation.
    • In the footnotes, footnote e should be deleted from table, removing the text reading: Safety in infants and children has not been established. Meropenem is preferred if a carbapenem is to be used in newborn infants. Posted 6/29/09
  9. Pages 784-810: The Medical Letter has informed the American Academy of Pediatrics of the following important pediatric dosage corrections in The Medical Letter table reprinted in the Red Book. In Table 4.9, the following changes should be made:
    • Page 789: Under CYCLOSPORIASIS (Cyclospora cayetanensis), the pediatric dosage for trimethoprim/sulfamethoxazole should be changed from TMP 5 mg/kg/SMX 25 mg/kg/d PO in 2 doses x 7-10d to TMP 10 mg/kg/SMX 50 mg/kg/d PO in 2 doses x 7-10d.
    • Page 793: Under GIARDIASIS (Giardia duodenalis), the pediatric dosage for quinacrine should be changed from 2 mg/kg/d PO in 3 doses x 5d (max 300 mg/d) to 6 mg/kg/d PO in 3 doses x 5d (max 300 mg/d).
    • Page 794: Under ISOSPORIASIS (Isospora belli), the pediatric dosage for trimethoprim/sulfamethoxazole should be changed from TMP 5 mg/kg/d/SMX 25 mg/kg/d PO in 2 doses x 10d to TMP 10 mg/kg/d/SMX 50 mg/kg/d PO in 2 doses x 10d.
    • Page 798: Under MALARIA, Treatment of, the pediatric dosage for tetracycline should be changed from 6.25 mg/kg/d in 4 doses x 7d to 25 mg/kg/d in 4 doses x 7d. Posted 7/17/09
    Additionally, the following change should be made:
    • Page 804: Under PNEUMOCYSTIS JIROVECI, the pediatric dosage for atovaquone for children over 24 mos should be changed from >24mos: 30 mg/d PO x 21d to >24mos: 30 mg/kg/d PO x 21d. Posted 1/13/10
    • Page 805: Under SCABIES, the pediatric dosage for 10% Crotamiton should be changed from Topically once/d PO x 2 to Topically once/d x 2. Posted 4/4/11